Amylyx Pharmaceuticals, Inc. Logo

Amylyx Pharmaceuticals, Inc.

Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.

AMLX | US

Overview

Corporate Details

ISIN(s):
US0321085088
LEI:
Country:
United States of America
Address:
43 THORNDIKE STREET, 2141 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing novel treatments for neurodegenerative diseases and other conditions with high unmet medical needs. The company advances a pipeline of investigational therapies based on rigorous science and well-defined mechanistic rationale. Key areas of focus in its pipeline include Amyotrophic Lateral Sclerosis (ALS), Wolfram syndrome, and Post-Bariatric Hypoglycemia. Amylyx is committed to a patient-centric approach, aiming to provide solutions for some of medicine's most complex challenges.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Amylyx Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amylyx Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amylyx Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Skye Bioscience, Inc. Logo
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
United States of America
SKYE
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway
SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan
4597
SOLENO THERAPEUTICS INC Logo
Develops novel therapeutics for rare diseases like Prader-Willi syndrome.
United States of America
SLNO
Sol-Gel Technologies Ltd. Logo
Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.
United States of America
SLGL
Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.